Honing Biosciences

About:

Bio-therapeutics company that develops and improves cell-based therapies in particular of cancer and other chronic diseases

Website: http://www.honing-biosciences.com/

Top Investors: Bpifrance, Elaia

Description:

Honing Biosciences is a bio-therapeutics company that develops and improves cell-based therapies in particular of cancer and other chronic diseases. Cell-based approaches represent a promising avenue to develop novel therapies. Honing Biosciences leverages technologies that allow precise control of cell functions after delivery to patients, increasing the efficacy and limiting the harmful drawbacks of previous generations of treatments. Our molecular CellTuneTM technology allows to develop new classes of tunable cell therapeutics to control the dynamic delivery of proteins in patients. We can thus regulate protein expression at the cell surface or secretion of enzymes, cytokines, antibodies, adapting the delivery of therapeutic proteins to clinical evolutions. Honing Biosciences proprietary technological platform has breakthrough applications all types of cell-based therapy, including immunotherapy and reconstituting cell therapies for autoimmunity and chronic diseases.

Total Funding Amount:

2M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Paris, Ile-de-France, France

Founded Date:

2018-06-18

Founders:

Abdelkader Bousabaa, Franck Perez

Number of Employees:

11-50

Last Funding Date:

2020-07-07

IPO Status:

Private

Industries:

© 2025 bioDAO.ai